MSCV-Luciferase-IRES-NrasG12D Citations (3)
Originally described in: Mouse models of human AML accurately predict chemotherapy response.Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W, McCurrach ME, Yang MM, Dolan ME, Kogan SC, Downing JR, Lowe SW Genes Dev. 2009 Apr 1;23(7):877-89. doi: 10.1101/gad.1771409. PubMed Journal
Articles Citing MSCV-Luciferase-IRES-NrasG12D
| Articles |
|---|
| CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to navitoclax. Neault M, Lebert-Ghali CE, Fournier M, Capdevielle C, Garfinkle EAR, Obermayer A, Cotton A, Boulay K, Sawchyn C, St-Amand S, Nguyen KH, Assaf B, Mercier FE, Delisle JS, Drobetsky EA, Hulea L, Shaw TI, Zuber J, Gruber TA, Melichar HJ, Mallette FA. Cell Rep. 2023 Sep 26;42(9):113084. doi: 10.1016/j.celrep.2023.113084. Epub 2023 Sep 15. PubMed |
Clec12a is required for the pathogenesis of NUP98::NSD1 AML.
Mohanty S, Charles Cano F, Gabdoulline R, Lai CK, Othman B, Sudarsanam H, Eder T, Grebien F, Lipka DB, Henschler R, Heuser M.
Blood Adv. 2025 May 7:bloodadvances.2024015739. doi: 10.1182/bloodadvances.2024015739.
PubMed
Associated Plasmids |
| Disparate leukemia mutations converge on nuclear phase-separated condensates. Datar GK, Khabusheva E, Anand A, Beale J, Sadek M, Chen CW, Potolitsyna E, Alcantara-Contessoto N, Liu G, De La Fuente J, Dollinger C, Guzman A, Martell A, Wohlan K, Maiti A, Short NJ, Yi SS, Andresen V, Gjertsen BT, Falini B, Rau RE, Brunetti L, Sahni N, Goodell MA, Riback JA. Cell. 2025 Dec 11;188(25):7118-7136.e21. doi: 10.1016/j.cell.2025.10.010. Epub 2025 Nov 4. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.